Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FFI-1010
- Development stage
- Unknown
- Lead developer
- Fuji Yakuhin
- Modality
- Small Molecules
01
Overview
FFI-1010 is a small molecule drug initially developed by Fuji Yakuhin Co., Ltd. for the treatment of urogenital diseases, with a specific focus on kidney disease in children under 18 years old. The drug has been evaluated in clinical trials to assess its safety and usability, particularly in pediatric populations with kidney disease. The primary objective of the Phase 3 study was to determine if the ratio of creatinine clearance (Ccr) to inulin clearance (Cin) measured at the same time is more than 1.2, which may indicate improved renal function or diagnostic utility[1][2]. The mechanism of action and specific molecular target are not publicly disclosed.
Beyond the preview
Go deeper on FFI-1010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FFI-1010.